Shares of Aveo Pharmaceuticals (AVEO) fall 17% premarket as the FDA asks the Oncologic Drugs Advisory Committee to help evaluate whether a single randomized trial is sufficient to warrant marketing approval for AVEO's renal cell carcinoma treatment tivozanib or whether further testing is necessary.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs